

PLATO: Ticagrelor ^{BRILLINTA} vs Clopidogrel ^{PLAVIX} in Acute Coronary Syndrome ¹

PLATElet inhibition and patient Outcomes trial

BOTTOM LINE

- Patients with a high risk of thrombosis & low risk of bleeding may benefit from ticagrelor. Caution in those with a history of COPD, asthma, HF, gout & severe renal impairment due to increased risk of dyspnea & elevated serum uric acid & creatinine.
- In **PLATO**, ACS patients ~60% NSTEMACS who received ticagrelor + ASA, versus clopidogrel + ASA, for a median of **9 months** had:
 - ↓ risk composite of death from vascular causes, MI, stroke (NNT=53)
 - Individual components of the composite: vascular death (NNT=91), MI (NNT=91), stroke (NS)
 - ↑ risk of non-CABG related major bleeding (NNH=167) & fatal bleeding non-intracranial NNH=500, intracranial NNH=1112
 - ↑ risk of dyspnea (NNH=17), & premature discontinuation of therapy (NNH=53)
- Based on the **PLATO** results, the **2012 Canadian Cardiovascular Society Antiplatelet Guidelines** recommend the following:²
 - Ticagrelor + ASA 81mg daily is preferred over clopidogrel + ASA 81mg daily x 12 months for:
 - STEMI with primary PCI Strong Recommendation, Moderate-Quality Evidence
 - NSTEMACS (medical management or revascularization) Strong Recommendation, High-Quality Evidence
- At time of publication, ticagrelor ^{BRILLINTA} ☎ \$108/month vs clopidogrel ^{PLAVIX}, g ☎ \$26/month.

BACKGROUND ^{1,2,3,4,5,6,7,8,9}

- Dual antiplatelet therapy (DAPT, i.e. ASA + clopidogrel/prasugrel/ticagrelor) is recommended after ACS (STEMI or NSTEMACS) to reduce the risk of thrombosis.
- Prior to **PLATO**, clopidogrel ^{PLAVIX} & prasugrel ^{EFFIENT} demonstrated a reduction in a composite endpoint of CV mortality, MI or stroke (always driven by a reduction in MI) with an associated increased risk in major bleeding. CURE, PCI-CURE, CLARITY, PCI-CLARITY, TRITON-TIMI
 - Clopidogrel, however, has inter-individual genetic variability that may result in poor antiplatelet response in some patients, irreversible antiplatelet effect, and a slower onset.
 - Prasugrel reduced CV mortality, MI or stroke more than clopidogrel, but it also increased the risk of major bleeding (including life-threatening and fatal bleeds). Prasugrel also resulted in net harm in those with a history of stroke/TIA and no net benefit was found in those ≥75yrs and ≤60kg. TRITON-TIMI
- Compared to clopidogrel and prasugrel, ticagrelor is not a pro-drug and is a reversible P2Y₁₂ inhibitor, resulting in more favourable pharmacokinetic effects such as rapid onset, offset, and lower inter-individual response.

TRIAL BACKGROUND ^{1,4}

DESIGN: randomized, double-blind, double dummy, international ^{43 countries}, multicentre ^{862 sites}, controlled trial. ITT & superiority for efficacy outcomes. Enrolment: October 2006 to July 2008. Funded by AstraZeneca (ticagrelor).

INTERVENTION: ticagrelor 180 mg LD followed by 90 mg BID vs clopidogrel 300-600mg LD followed by 75 mg daily, + ASA x 12 months (median 9 months). After coronary stenting, protocol allowed for ASA 325 mg for ≤6 months.

INCLUSION: ≥18yrs, hospitalized for ACS with onset during previous 24 hours

- **NSTEMACS:** ≥2 had to be met: a) ST segment changes indicating ischemia, b) positive biomarker, c) ≥1 risk factor: ≥60yrs, prior MI or CABG, CAD ≥50% stenosis in ≥2 vessels, prior ischemic stroke/TIA, carotid stenosis, cerebral revascularization, DM, PAD, CKD
- **STEMI:** both ST-segment elevation ≥0.1mV & planned primary PCI

EXCLUSION: Pregnant, CI to clopidogrel, use of fibrinolytic therapy <24 hrs before randomization, need for OAC, ↑ risk of bradycardia, strong CYP3A inhibitor/inducer, dialysis, clinically important thrombocytopenia or anemia

POPULATION at baseline: n=18,624, NSTEMACS (~60% NSTEMI 42.7%, UA 16.7%, n=11,067) & STEMI (37.7%, n=7026)

- Mean age 62yrs, ~15% ≥75yr, 28% female, ~92% Caucasian, ~2% from Canada; median body weight 80 kg, BMI 27 kg/m²
- ~65% HTN, ~46% dyslipidemia, ~36% smoker, ~25% DM, ~15% dyspnea, ~6% COPD, 5.5% HF, ~4% CKD, ~3% asthma, ~3% gout
- ~20% prior MI, ~13% prior PCI, ~6% prior CABG
- ~89% statin, ~89% beta blocker, ~75% ACEI, ~12% ARB, ~45% on PPI
- During the trial, 64% PCI (42% BMS, 18% DES), 10% CABG
- Clopidogrel LD: 60% received 300mg, 20% received 600mg
 - 46% of ticagrelor arm also received open-label clopidogrel LD prior to randomization (in addition to ticagrelor LD).
- ASA dose: overall, 97.5% 75-100 mg daily. 9.7% from North America; ~50% of the US sites: median ASA dose of ≥300mg daily.³

RESULTS

follow-up: median 277 days (9.2 months)

TABLE 1: EFFICACY (ITT ANALYSIS)

CLINICAL ENDPOINTS	TICAGRELOR 90 MG BID n=9333	CLOPIDOGREL 75 MG DAILY n=9291	HR (95% CI)	ARR	NNT / 9 MONTHS	COMMENTS	
PRIMARY EFFICACY ENDPOINT							
Death from vascular causes, MI or stroke	9.8%	11.7%	0.84 (0.77-0.92)	1.9%	53	• No difference in stroke, except ↑ risk of stroke of unknown cause (NNH=1250). • Difference between groups seen at 30 days and persisted throughout study. • The difference between ticagrelor & clopidogrel was NS in the following: - North American patients (p _{int} =0.045) - patients weighing less than median weight for their gender (males <82kg & females <71kg, p _{int} =0.04) - those not taking lipid lowering drugs at randomization (p _{int} =0.04)	
SECONDARY EFFICACY ENDPOINTS							
Death from vascular causes	4%	5.1%	0.79 (0.69-0.91)	1.1%	91		
MI	5.8%	6.9%	0.84 (0.75-0.95)	1.1%	91		
Stroke	1.5%	1.3%	1.17 (0.91-1.52)	NS	-		
Death from any cause	4.5%	5.9%	0.78 (0.69-0.89)	1.4%	72		
Death from any cause, MI, or stroke	10.2%	12.3%	0.84 (0.77-0.92)	2.1%	48		
Death from vascular causes, MI, stroke in subgroup with planned invasive tx	8.9%	10.6%	0.84 (0.75-0.94)	1.7%	59		
Death from vascular causes, MI, stroke, severe recurrent ischemia, recurrent ischemia, TIA or arterial thrombotic	14.6%	16.7%	0.88 (0.81-0.95)	2.1%	48		
Stent thrombosis (definite)	1.3%	1.9%	0.67 (0.5-0.91)	0.6%	167		

TABLE 2: ADVERSE EVENTS AND LAB ABNORMALTIES

OUTCOME OR ENDPOINT	TICAGRELOR 90 MG BID n=9235	CLOPIDOGREL 75 MG DAILY n=9186	HR (95% CI)	ARI	NNH / 9 MONTHS	COMMENTS
Fatal non-intracranial bleeding	0.1%	0.3%	RR 0.33	0.2%	500	<ul style="list-style-type: none"> • NS differences in the following: <ul style="list-style-type: none"> - major bleeding (trial or TIMI criteria) - bleeding requiring transfusion - life-threatening or fatal bleeding (study criteria) - intracranial bleeding - major or minor bleeding (TIMI criteria) - CABG related (procedural) - bradycardia - ventricular pauses ≥3 sec at 30 days • Clinical significance of elevated Scr & uric acid cannot be determined as study only reported % ↑ without indicating what the baseline mean was. <ul style="list-style-type: none"> - 1 month after end of tx, % ↑ for Scr & uric acid was NS.
Fatal intracranial bleeding	0.1%	0.01%	RR 10	0.09%	1112	
Non-CABG major bleeding (trial criteria)	4.5%	3.8%	1.19 (1.02-1.38)	0.7%	143	
Non-CABG major bleeding (TIMI criteria)	2.8%	2.2%	1.25 (1.03-1.53)	0.6%	167	
Major or minor bleeding (trial criteria)	16.1%	14.6%	1.11 (1.03-1.2)	1.5%	67	
Any dyspnea	13.8%	7.8%	1.84 (1.68-2.02)	6%	17	
Dyspnea requiring discontinuation	0.9%	0.1%	6.12 (3.41-11.01)	0.8%	125	
Ventricular Pauses ≥3 sec in first week	5.8%	3.6%	RR 1.61	2.2%	46	
Premature discontinuation	23.4%	21.5%	RR 1.09	1.9%	53	
Premature discontinuation due to AE	7.4%	6%	RR 1.23	1.4%	72	
Premature discontinuation due to unwillingness to continue	10.1%	9.2%	RR 1.03	0.9%	112	
↑ serum uric acid: baseline to 1 month	14% +/- 46%	7% +/- 44%	-	-	-	
↑ serum uric acid: baseline to 12 months	15% +/- 52%	7% +/- 31%	-	-	-	
↑ in Scr: baseline to 1 month	10% +/- 22%	8% +/- 21%	-	-	-	
↑ in Scr: baseline to 12 months	11% +/- 22%	9% +/- 22%	-	-	-	

STRENGTHS, LIMITATIONS, & UNCERTAINTIES

- STRENGTHS:**
- Clinically meaningful endpoints (death from vascular causes, MI, stroke).
 - ITT analysis of efficacy outcomes
 - Only 5 patients lost to follow up (0.03%)
- LIMITATIONS:**
- Only 2.2% (n=401) of patients were from Canada.^{1,3}
 - The independent data & safety monitoring board had access to unblinded data.
 - 46% of patients randomized to ticagrelor received both clopidogrel and ticagrelor loading dose.
 - Variability existed in clopidogrel loading dose (300 to 600 mg).
 - >20% discontinued treatment prematurely
 - Potential lack of ticagrelor efficacy in North Americans (n=1814, US n=1413, Canada n=401), lower weight patients, and those not taking lipid lowering therapies at randomization. Subgroup analysis of geographic location showed significantly higher proportion of Americans received median ASA dose ≥300 mg vs rest of world (53.6% vs 1.7%). As such, ASA <100 mg/day is the recommended dose when combined with ticagrelor.³
 - Of the 64% who underwent PCI, only 18% received DES. DES have largely replaced BMS in current practice.
- UNCERTAINTIES:**
- Safety of ticagrelor in patients with pulmonary diseases (dyspnea), bradycardia/heart block (ventricular pauses), renal dysfunction (elevation in Scr), & gout (elevation in uric acid). There was a low percentage of patients with a history of COPD, asthma, CHF, gout, & CKD included in the study.
 - Unclear if allocation was concealed.

RxFILES RELATED LINKS

- Duration of DAPT & Triple Therapy RxFiles Chart
- **DAPT** RxFiles Trial Summary: <http://www.rxfiles.ca/rxfiles/uploads/documents/DAPT-Trial-12vs30months.pdf>
- **PCI-CLARITY** RxFiles Trial Summary: <http://www.rxfiles.ca/rxfiles/uploads/documents/PCI-CLARITY%20Trial%20Summary.pdf>
- **PCI-CURE** RxFiles Trial Summary: <http://www.rxfiles.ca/rxfiles/uploads/documents/PCI-CURE%20Trial%20Summary.pdf>
- **TRITON-TIMI** RxFiles Trial Summary: <http://www.rxfiles.ca/rxfiles/uploads/documents/TRITON-TIMI%2038%20Trial%20Summary.pdf>

©=not covered by NIH B=Exceptional Drug Status in SK ACEI=angiotensin converting enzyme inhibitor ACS=acute coronary syndrome AE=adverse event ARB=angiotensin II receptor blocker ARI=absolute risk increase ARR=absolute risk reduction ASA=acetylsalicylic acid BID=twice daily BMI=body mass index BMS=bare metal stent CABG=coronary artery bypass grafting CAD=coronary artery disease CI=confidence interval/contraindicated CKD=coronary artery disease COPD=chronic obstructive pulmonary disease CV=cardiovascular CYP3A=cytochrome P450 3A, DAPT=dual antiplatelet therapy DES=drug-eluting stent DM=diabetes mellitus HF=heart failure HR=hazard ratio hr=hour HTN=hypertension ITT=intention to treat LD=loading dose MI=myocardial infarction NNT=number needed to treat NNH=number needed to harm NS=non-statistically significant NSTEACS=non ST-elevated ACS NSTEMI=non ST-elevated MI OAC=oral anticoagulant PAD=peripheral artery disease PCI=percutaneous coronary intervention p_{int}=statistically significant for the interaction PPI=proton pump inhibitor RR=relative risk SCR=serum creatinine sec=seconds STEMI=ST-elevated myocardial infarction TIA=transient ischemic attack TIMI=thrombolysis in MI tx=treatment UA=unstable angina US=United States yr=year

ACKNOWLEDGEMENTS: Prepared By: Danielle Shmyr, Lynette Kosar, Brent Jensen, Loren Regier

DISCLAIMER: The content of this newsletter represents the research, experience and opinions of the authors and not those of the Board or Administration of Saskatoon Health Region (SHR). Neither the authors nor Saskatoon Health Region nor any other party who has been involved in the preparation or publication of this work warrants or represents that the information contained herein is accurate or complete, and they are not responsible for any errors or omissions or for the result obtained from the use of such information. Any use of the newsletter will imply acknowledgment of this disclaimer and release any responsibility of SHR, its employees, servants or agents. Readers are encouraged to confirm the information contained herein with other sources. Additional information and references online at www.RxFiles.ca Copyright 2016 – RxFiles, Saskatoon Health Region (SHR)

References:

1. Wallentin, A Becker R, Budaj A, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes **PLATO**. N Engl J Med. 2009 Sep 10;351(11):1045-1056.
2. Tanguay JF, Bell AD, Ackman ML, et al; **Canadian Cardiovascular Society**. Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. Can J Cardiol. 2013 Nov;29(11):1334-45.
3. Mahaffey KW, Wojdyla DM, Carroll K, et al; **PLATO Investigators**. Ticagrelor compared with clopidogrel by **geographic region** in the Platelet Inhibition and Patient Outcomes **PLATO** trial. Circulation. 2011 Aug 2;124(5):544-54.
4. James S, Akerblom A, Cannon CP, Emanuelsson H et al. Comparison of ticagrelor, the first reversible oral P2Y₁₂ receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATElet inhibition and patient Outcomes (**PLATO**) trial. Am Heart J. 2009 Apr;157(4):599-605.

5. CURE Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (**CURE**) trial programme. *Eur Heart J* 2000, 21:2033-2041.
6. Mehta SR, Yusuf S, Peter RJG, Bertrand ME, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the **PCI-CURE** study. *Lancet* 2001. 358:527-533.
7. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of Clopidogrel Pretreatment Before Percutaneous Coronary Intervention in Patients with ST-Elevation Myocardial Infarction Treated with Fibrinolytics: The **PCI-CLARITY** Study. *JAMA*. 2005 Sept 14; 29=4 (10): 1224-1232.
8. Sabatine MS, Cannon CP, Gibson CM, et al; **CLARITY-TIMI 28** Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. *N Engl J Med*. 2005 Mar 24; 352(12):1179-89.
9. Wiviott SD, Braunwald E, McCabe CH, et al; **TRITON-TIMI 38** Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2007 Nov 15; 357(20):2001-15.